Cybin

Cybin: Positive Data Announced From Innovative Drug Trial
Sponsored
Cybin: Psychedelic Based BioPharma Company To Announce Much Anticipated Updates For Its Ongoing Clinical Trials
Sponsored
Cybin Approved For First In-Human Dosing Of DMT Molecule CYB004, Milestone For Anxiety Disorder Treatment
Cybin: Psychedelic Based BioPharma Company To Announce Much Anticipated Updates For Its Ongoing Clinical Trials
Sponsored
Cybin Approved For First In-Human Dosing Of DMT Molecule CYB004, Milestone For Anxiety Disorder Treatment
Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family
BREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat Depression

Cybin Recent News

Cybin Presents "Why Cybin Is Investing So Heavily On Developing Novel Psychedelic Molecules" At The Psychedelic Capital Conference
Photo by Presetbase Lightroom Presets on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Sponsored
Cybin's Major Depressive Disorder Treatment Trials Continue With Clinilabs Drug Development Corp
Three weeks after announcing the results of its preclinical trials for CYB003, Cybin (NYSE:CYBN) made public a partnership with Clinilabs Drug Development Corporation to take the proprietary drug to it
Cybin's CYB0004 Shows Positive Preclinical Results Over Traditional Psychedelics
WIPO Publishes Cybin's Patent Application For Inhaled Psychedelics Therapies
A Builder From The Ground Up, Doug Drysdale, CEO of Cybin: Meet Our Speakers
Cybin Begins Study Using Kernel Flow Headsets To Measure Ketamine's Effects On The Brain
Cybin Completes In Vivo Preclinical Studies For Major Depressive Disorder
Five Companies Developing Second Generation Psychedelics For Mental Health
Cybin Reports Q2 Financial Results And Latest News, Including FDA & DEA Research Approvals
Toronto-based, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics,” reported its unaudited financial results on Monday for the second quarter ended September 30, 2021.
FDA Authorizes Cybin Device To Quantify Psychedelics' Effects On The Brain
This article was originally published on Psychedelic Spotlight and appears here with permission.
Cybin Announces Positive Data Showing Effectiveness of Psilocybin To Treat Depression
Cybin Inc (NYSE: CYBN), a Toronto-based biotechnology company focused on utilizing psychedelic drugs as an alternative to traditional psychiatric drugs, announced positive pre-clinical data, indicating that its drug, CYB003 showed strong signs of cognitive improvement in patients with Major Depressive Disorder
Cybin: FDA Authorizes Feasibility Study To Measure Ketamine's Effect On Cerebral Cortex
Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced Wednesday that the U.S.
Cybin Inc. CEO To Present In Two Upcoming Investor Conferences
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Sponsored
Cybin Inc. Likely To Benefit From New Research Touting Psilocybin Mental Health Treatments
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Sponsored
Cybin Inc. (NEO: CYBN) (NYSE: CYBN) Files Two International Patent Applications In Support Of The Company's Research Phase Programs
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Sponsored
VIDEO: How Is Cybin Taking On Mental Healthcare? | Benzinga Global Small Cap Conference
The Benzinga Global Small Cap Conference bridges the gap between Small Cap companies, investors, and traders. Learn about small cap investing with clearly defined Educational Modules, take a look at a curated group of Small Cap investment opportunities, and connect with the global Small Cap audience in an intimate, virtual setting.
Psyched: California Psychedelics Bill Passes Second Committee, GH Research Closes $125M Series B, Study Shows Psilocybin Could Equal SSRI Results In Depression
A bill that would remove penalties for the possession, personal use and social sharing of certain natural and synthetic psychedelics in California passed the state Senate Health Committee. The bill will now be reviewed by the Senate Appropriations Committee, after which it would move to a Senate floor vote if approved.
Psyched: Compass' New Patents, Cure Extends DEA License, Andrew Yang Supports Psilocybin in NYC
Compass Secures 2 New Patents In the midst of a public debate about the right use of patents in the psychedelics sector, Compass Pathways (NASDAQ: CMPS) was granted two new patents by the US Patent and Trademark Office.
The Horizons Psychedelic Stock Index ETF, As Told By Its Fund Manager
On January 27, the Horizons Psychedelic Stock Index ETF (NEO:PSYK) became the first exchange traded fund to focus solely on the psychedelics industry. 
First Psychedelics ETF Debuts On NEO Exchange
The Horizons Psychedelic Stock Index ETF is now listed on Toronto’s NEO exchange under the symbol ‘PSYK.’ PSYK is the first exchange traded fund providing exposure to the burgeoning industry of medicinal psychedelics.
Psyched: Compass Launches Center Of Excellence, Entheon Purchases HaluGen, Atai Buys Majority Stake In Recognify
Compass Launches Center Of Excellence Compass Pathways (NASDAQ: CMPS) officially launched the Centre of Excellence, in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland.
Psyched: Canada Allows Psilocybin Use For Healthcare Pros, UK Begins DMT Trials, Cybin To Purchase Adelia
Canada Allows Professionals In Training To Use Psilocybin The Canadian Health Minister Patty Hajdu has allowed 17 healthcare professionals to possess and use psilocybin to conduct professional training in psilocybin-assisted therapy.
Psyched: CA Discusses Decriminalization, Compass Holds Earnings Call, Psychedelics Hotline To Launch
California’s legislature could soon be discussing a new bill meant to decriminalize psychedelic substances.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved